関連する実験動画
Updated: May 11, 2026
09:28
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
アデノシンは,ウサギのヴァガルアファレントニューロンにおけるハイパーポラライゼーション後の遅いポストスパイクを阻害することにより,神経刺激性を高めます
H R Middlekauff1, A Doering, J N Weiss
1Cardiovascular Research Laboratory, Departments of Medicine (Cardiology) and Physiology, Los Angeles, CA, USA. hmiddlek@medicine.medsch.ucla.edu
Circulation
|March 10, 2001
まとめ
アデノシン (Adenosine) は,緩やかなアフターハイパーポラライゼーション (AHPs) を阻害することによって,ヴァガルニューロンの興奮性を高めます. この効果は,A(2A) -アデノシン受容体によって媒介され,おそらくは,カルシウムチャネル阻害ではなく,cAMPの生産の増加によるものです.
科学分野:
- 神経科学は神経科学である.
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- アデノシンによる心臓アファレントニューロンの活性化の電気生理学的メカニズムは不明である.
- 静脈C線維の遅い後高分極化 (AHP) はニューロンの興奮性を低下させる.
- 神経信号伝達におけるアデノシンの役割を理解することは,心臓血管研究にとって極めて重要です.
研究 の 目的:
- アデノシンが遅いAHPsを阻害することによって,ヴァガルニューロンの興奮性を増加させるかどうかを調査する.
- これらの効果に起因する特定のアデノシン受容体のサブタイプを特定する.
主な方法:
- 培養された成人ウサギのノドーゼ・ギャングリアン細胞に穿孔パッチ・クランプ技術を使用しました.
- アクションポテンシャル応答率を評価するために,電流パルスの列車で刺激されたニューロン.
- アデノシンと選択的なアデノシン受容体アゴニスト/アンタゴニストを適用し,遅いAHPと興奮力への影響を評価しました.
主要な成果:
- アデノシン (10 μmol/L) は遅いAHPを著しく抑制し,アクションポテンシャル応答率を3.8%から28%に増加させた.
- A(2) -アデノシン受容体アゴニストであるNECAは,A(1) アゴニストであるCCPAではないが,アデノシンの効果を模倣した.
- A(2A) 反抗体ZM 241385はアデノシンの作用を阻害したが,A(1) 反抗体DPCPXはそうしなかった.
結論:
- アデノシンは,ヴァーガルアフェレントニューロンにおける遅いAHPを効果的に抑制します.
- A(2A) -アデノシン受容体は,この効果の主な媒介体である.
- I(Ca) 阻害ではなく,cAMPの生産の増加が,アデノシンの作用の根底にある可能性が高いメカニズムです.
関連する概念動画
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...